Large-scale manufacturing of oligonucleotides could become more environmentally friendly if the biotech industry can overcome the challenges of a promising technique for synthesizing them. That’s ...
Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymat ...
Hongene Biotech shows advanced oligonucleotide CDMO capabilities via support of SiranBio’s dual-target siRNA programme: Singapore Saturday, May 9, 2026, 16:00 Hrs [IST] Hongene ...
Research and Development expenses for the first quarter of 2026 were $11.4 million compared to $12.9 million in the first quarter of 2025. The decrease was primarily due to lower allocable costs, ...
Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial The primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results